迪卡斯(Delcath Systems)宣布,其用于治疗肝脏主导型转移性乳腺癌的药物Hepzato™,已在二期临床试验中为首位患者完成给药。这一进展标志着该创新疗法的临床开发迈出了关键一步。
迪卡斯(Delcath Systems)宣布,其用于治疗肝脏主导型转移性乳腺癌的药物Hepzato™,已在二期临床试验中为首位患者完成给药。这一进展标志着该创新疗法的临床开发迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.